The stress response: implications for the clinical development of hsp90 inhibitors.
about
Corresponding functional dynamics across the Hsp90 Chaperone family: insights from a multiscale analysis of MD simulationsCrystal structure of the hexamer of human heat shock factor binding protein 1Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeuticsProteotoxic stress and inducible chaperone networks in neurodegenerative disease and agingSingle Prolonged Stress induces ATF6 alpha-dependent Endoplasmic reticulum stress and the apoptotic process in medial Frontal Cortex neurons.Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsTo fold or not to fold: modulation and consequences of Hsp90 inhibition.Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer.BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapyA first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicHSP90 supports tumor growth and angiogenesis through PRKD2 protein stabilization.The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer.The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.Heat shock response modulators as therapeutic tools for diseases of protein conformation.HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells.HSP90: a rising star on the horizon of anticancer targets.HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemiaMolecular chaperones and selection against mutationsTherapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy.Inhibitors of the heat shock response: biology and pharmacology.Alcohol exposure regulates heat shock transcription factor binding and heat shock proteins 70 and 90 in monocytes and macrophages: implication for TNF-alpha regulation.Cisplatin abrogates the geldanamycin-induced heat shock responsePhase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE.New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.Targeting Hsp90: small-molecule inhibitors and their clinical development.P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion.Heat shock proteins in diabetes and wound healingKU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cellsAlternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.Protein folding, protein homeostasis, and cancer.Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer.
P2860
Q27331720-57439A31-6C93-4F67-B26A-02DAAF28D0C5Q27651944-D081A8C2-A0B9-4758-B4A2-883A4C3FE849Q27679845-3F813DD5-14E9-4EE8-AEA1-9B79944C42C4Q28254233-BEB91116-514B-4A29-9D0C-E31FCD188230Q29614783-5F7F67D9-FC9A-4D25-B748-66496ACE9777Q30426463-31E321F9-689C-4E7D-83FE-1F85FA3C40B8Q33387877-734158E7-C594-466B-BD65-6B1DC63E555CQ33531705-502196AE-5732-433D-9FA0-4B5C3BFC47BFQ33848888-346CE33F-E61D-4D55-B066-F17D42E5DF54Q34360164-5E64EAAA-843B-4763-A913-856E2D7F27F8Q34636437-84ED9790-BDC4-4500-8A67-3862C9572475Q34765294-ADE925AF-4934-4324-A1A8-F1F3DAD04F8EQ34817365-7BAE88F8-900F-4BF8-98E3-FF5BCE22612BQ35044046-60880F77-E13B-49E0-9A9C-13872F5B655AQ35164144-C96334AC-0550-47C8-8798-94C8302CB3B5Q35546764-B869FB59-037D-4727-BD15-5B6990A562D1Q35606420-5125B82D-0F69-471C-A6CE-9DC22BC691EDQ35849973-6C6E3475-1CAD-4EA8-B3B9-7CFD388F1069Q36217181-1A97A8B9-F0EB-47C8-8A70-4D0C65C09FB9Q36237528-9269D736-432B-4845-9579-605EFCFEC8CDQ36429542-61D5916C-2248-4C45-9CEB-ACAE44FD8056Q36436934-D5C3A62A-3E7E-4D4B-8A59-86882F6BB754Q36496399-00F12FD3-345C-43D7-9E14-D22FADCB119AQ36499222-EB825151-9AFE-4B14-A3E5-531B1ED1A5C8Q36759577-A0D6B746-2734-43AF-996E-268ECCF520A1Q36845355-999B7E5F-8B5D-4631-83A6-88EF70C36EB8Q36938491-C30D1A8E-44EB-414C-B9BC-F2037C20C1C1Q36948038-6F95E809-22C3-46C2-B304-A9139A623FD3Q36999363-FBB0D615-F519-44C6-AE80-7D70A5354D8CQ37010253-F6E8C77C-4720-4391-BA95-589B75A93F0CQ37215989-1F1FB464-C959-46E1-B476-AE0BB50DF75CQ37222845-389A0A9D-6E43-491B-823D-F241B80F3677Q37226339-840C4BA4-C7D3-494B-A8B3-A08A6AD3EE91Q37369580-02E710A8-0E5B-48FF-9E6B-459D9EE5AD31Q37411519-94EED6B1-46F5-47F4-9224-381E882BAF97Q37444497-4B4830B3-EE55-4BEC-AD8D-5A19100F030AQ37622446-D3FB8780-F67F-4629-AF86-FEC0282381B5Q37772399-43A8A830-C87C-4C12-946C-DD4AB2C57E6EQ37832796-7359CEBC-0861-4FF5-A899-7DE6001304B4Q38261693-CD4DC61D-573C-461A-9433-E62DD8552AF7
P2860
The stress response: implications for the clinical development of hsp90 inhibitors.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The stress response: implications for the clinical development of hsp90 inhibitors.
@ast
The stress response: implications for the clinical development of hsp90 inhibitors.
@en
type
label
The stress response: implications for the clinical development of hsp90 inhibitors.
@ast
The stress response: implications for the clinical development of hsp90 inhibitors.
@en
prefLabel
The stress response: implications for the clinical development of hsp90 inhibitors.
@ast
The stress response: implications for the clinical development of hsp90 inhibitors.
@en
P356
P1476
The stress response: implications for the clinical development of hsp90 inhibitors.
@en
P2093
Rochelle Bagatell
Ryan Falsey
P304
P356
10.2174/1568009033481787
P577
2003-10-01T00:00:00Z